Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – C-o-group doai
Patent
1995-06-07
1999-10-19
Weber, Jon P.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
C-o-group doai
514559, 514560, 424 854, A01N 3104, A01N 3700, A61K 3821
Patent
active
059689897
ABSTRACT:
In accordance with the present invention, there are provided methods to modulate processes mediated by retinoid receptors, employing high affinity, high specificity ligands for such receptors. In one aspect of the present invention, there are provided ligands which are more selective for the retinoid X receptor than is retinoic acid (i.e., rexoids). In another aspect of the present invention, alternative ligands (other than retinoic acid) have been discovered which are capable of inducing retinoic acid receptor mediated processes. In yet another aspect, methods have been developed for the preparation of such retinoid receptor ligands from readily available compounds.
REFERENCES:
patent: 4216312 (1980-08-01), Rosenberger
patent: 5183817 (1993-02-01), Bazzano
patent: 5192534 (1993-03-01), Grollier et al.
patent: 5219888 (1993-06-01), Katocs, Jr. et al.
patent: 5399586 (1995-03-01), Davies et al.
patent: 5428071 (1995-06-01), Bollag et al.
patent: 5455265 (1995-10-01), Chandraratna
patent: 5466861 (1995-11-01), Dawson et al.
patent: 5475113 (1995-12-01), Chandraratna
Akita et al. (1980) J. Am. Chem. Soc., 102, "Nonbleachable Rhodopsins Retaining the Full Natural Chromophore", pp. 6370-6372.
Eager et al. (1991) FEBS, 292(1,2), "A Member of the Chicken RXR Family of Nuclear Receptors Activates Transcription in Response to Retinoic Acid", pp. 103-106.
Levin et al. (1992) Nature, 355, "9-Cis Retinoic Acid Stereoisomer Binds and Activates the Nuclear Receptor RXR.alpha.", pp. 359-361.
Lehmann et al. (1992) Science, "Retinoids Selective for Retinoid X Receptor Response Pathways", pp. 1944-1946.
Yen et al. (1986) Leukemia Res., 10(6), "Retinoic Acid Induced HL-60 Myeloid Differentiation: Dependence of Early and Late Events on Isomeric Structures", pp. 619-629.
Boehm Marcus F.
Eichele Gregor
Evans Ronald M.
Heyman Richard A.
Mangelsdorf David J.
Baylor College of Medicine
Kim Stanley H.
Ligand Pharmaceuticals Inc.
Reiter Stephen E.
The Salk Institute for Biological Studies
LandOfFree
Means for the modulation of processes mediated by retinoid recep does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Means for the modulation of processes mediated by retinoid recep, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Means for the modulation of processes mediated by retinoid recep will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2056042